MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms

Phase 3
Recruiting
Conditions
Vasomotor Symptoms
Interventions
First Posted Date
2022-12-05
Last Posted Date
2023-02-08
Lead Sponsor
Cairo University
Target Recruit Count
146
Registration Number
NCT05637671
Locations
🇪🇬

Dar El-Salam Cancer Hospital, Cairo, Governorate, Egypt

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

Phase 1
Completed
Conditions
Hypercapnia
Ventilatory Depression
Interventions
First Posted Date
2022-07-22
Last Posted Date
2023-11-09
Lead Sponsor
Food and Drug Administration (FDA)
Target Recruit Count
27
Registration Number
NCT05470465
Locations
🇺🇸

Spaulding Clinical Research, West Bend, Wisconsin, United States

EEG Results of Deep TMS in Patients With OCD

Not Applicable
Conditions
Obsessive-Compulsive Disorder
EEG With Periodic Abnormalities
Interventions
Device: Deep Transcranial Magnetic Stimulation
First Posted Date
2022-01-12
Last Posted Date
2022-01-12
Lead Sponsor
Istanbul Medipol University Hospital
Target Recruit Count
30
Registration Number
NCT05188833
Locations
🇹🇷

Istanbul Medipol University, Istanbul, Beykoz, Turkey

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-01-03
Last Posted Date
2024-03-13
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
24
Registration Number
NCT05175430
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-07-29
Last Posted Date
2021-09-05
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Target Recruit Count
74
Registration Number
NCT04981704
Locations
🇺🇸

Celerion, Phoenix clinical facility, Tempe, Arizona, United States

To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
First Posted Date
2021-05-17
Last Posted Date
2021-08-04
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
24
Registration Number
NCT04888728
Locations
🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

Phase 1
Active, not recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2021-02-17
Last Posted Date
2024-02-01
Lead Sponsor
Sadat City University
Target Recruit Count
100
Registration Number
NCT04757571
Locations
🇪🇬

Faculty of Pharmacy, Shibīn Al Kawm, Menoufia, Egypt

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Phase 1
Completed
Conditions
Drug-drug Interaction
Interventions
First Posted Date
2020-12-02
Last Posted Date
2022-07-15
Lead Sponsor
HUYABIO International, LLC.
Target Recruit Count
39
Registration Number
NCT04650542
Locations
🇺🇸

Spaulding Clinical, West Bend, Wisconsin, United States

🇦🇺

Nucleus Network Pty Ltd., Melbourne, Victoria, Australia

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

First Posted Date
2020-06-24
Last Posted Date
2024-12-09
Lead Sponsor
Pfizer
Target Recruit Count
370212
Registration Number
NCT04446039
Locations
🇰🇷

Pfizer, Seoul, Korea, Republic of

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

Phase 1
Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2020-03-17
Last Posted Date
2022-01-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
38
Registration Number
NCT04311463
Locations
🇲🇽

GSK Investigational Site, Monterrey, Nuevo León, Mexico

© Copyright 2025. All Rights Reserved by MedPath